◆ NeutralUNCY
Bronstein, Gewirtz & Grossman LLC Urges Unicycive Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
GlobeNewswire Inc.·
A class action lawsuit has been filed against Unicycive Therapeutics, Inc. alleging that the company made materially false and misleading statements regarding its third-party manufacturing vendor's FDA compliance. The lawsuit claims Unicycive failed to properly audit the vendor's facility and lacked reasonable basis for believing deficiencies were remedied, creating material risk of regulatory delays for oxylanthanum carbonate approval. Investors who purchased securities between December 29, 2025 and June 29, 2026 are encouraged to join the case, with a lead plaintiff deadline of November 2, 2026.
Read Full Article at GlobeNewswire Inc. →